Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Endometrial Neoplasms 2 Breast Neoplasms 2 Smoking 1 Rectal Neoplasms 1 Pulmonary Disease, Chronic Obstructive 1 Peripheral Nervous System Diseases 1 Overweight 1 Obesity 1 Motor Activity 1 Meningioma 1 Medulloblastoma 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Localized Prostate Cancer 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Infertility 1 HER2 IHC3+ Advanced Colorectal Cancer 1 Genetic Diseases, Inborn 1 Cognitive Dysfunction 1

Interventions

Capecitabine 22 Oxaliplatin 19 Fluorouracil 16 Radiotherapy 11 Leucovorin 10 Cetuximab 9 Nivolumab 7 Bevacizumab 6 sintilimab 5 Specimen Handling 5 Radiotherapy, Intensity-Modulated 5 Magnetic Resonance Spectroscopy 5 Irinotecan 5 Folfox protocol 5 trifluridine tipiracil drug combination 4 pembrolizumab 4 Surgical Procedures, Operative 4 encorafenib 3 X-Rays 3 Trastuzumab 3 Surveys and Questionnaires 3 Sigmoidoscopy 3 Radiation 3 Pemetrexed 3 Gemcitabine 3 Endoscopy 3 Control Groups 3 Consolidation Chemotherapy 3 Cisplatin 3 Carboplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rectal Neoplasms × Tablets × 90 days × Clear all

NCT04503694 2026-05-22

REGINA

Jules Bordet Institute

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡